Nrf2 Signaling Pathway: Biological Function, Clinical Implications and Therapeutic Agents—2nd Edition
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1227
Special Issue Editor
Interests: therapetiuc agents targeting Keap1-Nrf2-ARE signaling; redox system-related prodrugs and probes; innovative molecules acting on protein complex; E3 ligase complex
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Our previous Special Issue, entitled “Nrf2 Signaling Pathway: Biological Function, Clinical Implications and Therapeutic Agents” (https://www.mdpi.com/journal/antioxidants/special_issues/Nrf2_Signaling_Pathways) and published in the 2023 volume of Antioxidants, was a successful compilation of research and review articles. As this is a rapidly evolving topic, we would like to further explore Nrf2 and oxidative stress in human disease with a follow-up Special Issue in 2024.
Nrf2 is a multifunctional transcription factor that plays a crucial role in the cytoprotective system. Enhancing Nrf2 activity has long been regarded as a promising means by which to treat a set of diseases that appear to be mechanistically linked with oxidative stress. In addition, growing evidence indicates that the overactivation of Nrf2 plays a vital role in tumour occurrence and malignant transformation. In the last decade, an expanding body of research has focused on blocking NRF2 activity in cancer cells, attempting to disturb the redox balance, antagonizing the oncogenic metabolism, and reversing the resistance to treatment. Thus, the properly timed and fine-tuned manipulation of Nrf2 signalling is critical for the development of clinical drugs.
This Special Issue aims to collect research articles and review papers addressing all aspects of Nrf2. Papers describing new findings pertaining to the biological function of Nrf2, the fresh clinical implications of Nrf2-targeting agents and the development of Nrf2-targeting therapeutic agents will be especially welcome. Insightful review papers attending to the relevant fields are also favored.
Dr. Zhengyu Jiang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Nrf2
- Keap1
- oxidative stress
- ROS
- inflammation
- cancer
